Menopause Treatment

HRT Patches vs Gel vs Pills: Not All Estrogen Is Created Equal

Three women walk into a pharmacy with the same prescription — estradiol. One leaves with a box of patches. One with a tube of gel. One with a bottle of tablets. They’ll take the same drug by three completely different routes, and their bodies will process it in radically different ways.

The delivery method matters as much as the hormone itself. A transdermal patch feeds estrogen directly into your bloodstream through your skin, bypassing your liver entirely. Oral estradiol goes through your digestive system and hits your liver first, where about 90% of the dose gets metabolized before it ever reaches your circulation. Gel sits somewhere in between — transdermal like the patch, but with more flexible dosing and no adhesive on your skin.

Choosing the right method isn’t about preference. It’s about your medical history, your symptom pattern, your lifestyle, and your risk profile. Here’s what the evidence says about each option. For a complete comparison of all HRT forms including implants and spray, see our guide on menopause HRT options.

Estrogen Patches: The Steady-State Champion

Patches deliver a continuous, controlled dose of 17β-estradiol through the skin over 3 to 7 days depending on the brand. The estradiol enters the bloodstream directly through the dermal capillaries, avoiding first-pass hepatic metabolism entirely. This means the liver doesn’t break down the estrogen before it can work, so you need less hormone to achieve therapeutic blood levels.

The Canadian Agency for Drugs and Technologies in Health published a rapid review in January 2025 comparing transdermal versus oral menopausal hormone therapy. The review concluded that transdermal estradiol is associated with a lower risk of venous thromboembolism — roughly the same background risk as a woman not taking HRT. Oral estrogen, by contrast, increases VTE risk by 2- to 4-fold because the liver produces more clotting factors when it processes the first pass. For women with a history of migraine with aura, high blood pressure, or clotting disorders, transdermal is the preferred route.

That’s the good news. The bad news is skin reactions. A significant number of women — estimates range from 10 to 25% depending on the brand — develop contact dermatitis from the patch adhesive. The reaction is usually to the adhesive components or chemical penetration enhancers, not the estradiol itself. Rotating application sites between the lower abdomen, buttocks, and upper thigh can help. Switching to a different brand sometimes resolves the issue because each manufacturer uses a different adhesive formula.

One weird detail: the Climara 50 mcg patch is roughly the size of a matchbook, while the Vivelle-Dot 0.05 mg patch is about the size of a dime. Despite the size difference, both deliver the same amount of estradiol per day. The smaller patch uses a different matrix technology that concentrates the hormone into a smaller adhesive area.

Estradiol Gel: Dosing Freedom With a Transfer Risk

Estradiol gel — brands like EstroGel, Divigel, and Elestrin — is a clear, alcohol-based gel you apply to your arm, shoulder, or thigh once daily. Like patches, it’s transdermal, meaning it bypasses the liver and carries the same reduced clotting risk. But gel differs from patches in one critical way: you control the dose from pump to pump.

Gel allows finer dose adjustments than patches. A single pump of EstroGel delivers 0.75 mg of estradiol. You can take one pump, one and a half pumps, two pumps — whatever your symptoms require. Patches come in fixed strengths: 0.025, 0.0375, 0.05, 0.075, and 0.1 mg/day. If one strength is too much and the next is too little, you’re stuck. Gel solves that problem.

The trade-off is transfer risk. A Frontiers in Endocrinology study published June 10, 2025, from researchers at Changsha Hospital measured estradiol contamination on skin after gel application at various time points. At 10 minutes after application, skin estradiol levels measured 205 pg/mL in the gel group. After just 60 seconds of physical contact, the contact group showed 66 pg/mL of transferred estradiol — enough to affect another person. At 60 minutes post-application, skin levels dropped to 99 pg/mL in the gel group and just 8 pg/mL after contact. The recommendation: wait at least 60 minutes after applying gel before letting anyone touch your application site. Avoid contact with children, partners, and pets entirely if possible.

Drying time matters too. EstroGel takes roughly 2 to 5 minutes to dry on the skin. If you apply it and immediately pull on a sleeve, some of the gel transfers to the fabric instead of absorbing into your skin. The 2025 Canadian comparative review noted that women who applied gel to a 200 cm² area — about the size of a standard sheet of printer paper folded in half — achieved 2-fold higher bioavailability compared to spreading over a larger area.

Oral Estradiol Pills: Cheap, Effective, and Riskier

Oral estradiol is the oldest and most studied delivery method. It’s also the cheapest — generic 17β-estradiol tablets cost between $4 and $25 per month without insurance through most pharmacy discount programs. But cheap doesn’t mean better. The oral route subjects estradiol to extensive first-pass metabolism in the gut and liver, converting much of the dose into estrone and estrone sulfate rather than maintaining estradiol levels.

The clinical consequence of this metabolic conversion is measurable. Women on oral estradiol have higher levels of estrone than estradiol in their bloodstream — a hormonal profile that doesn’t match what their ovaries produced before menopause. For most women, this doesn’t matter for symptom relief. But the first-pass effect also triggers the liver to produce more clotting factors, angiotensinogen, and sex hormone-binding globulin. These changes increase the risk of venous thromboembolism, raise blood pressure in susceptible women, and elevate triglyceride levels.

The AAFP clinical guideline on menopause management published in February 2026 specifically recommends transdermal over oral estrogen for women with a history of VTE, obesity (BMI > 30), hypertension, or elevated triglycerides. For healthy women under 60 without these risk factors, oral estradiol remains a perfectly reasonable choice. The absolute risk difference is small: oral estradiol increases VTE risk from roughly 1 per 10,000 women per year to 2 to 4 per 10,000. But “small” matters when you’re that one woman.

One 2024 meta-analysis of 14 observational studies totaling over 1.2 million women found that transdermal estrogen had a VTE risk of 0.9 per 1,000 person-years — statistically identical to non-users — while oral estrogen had a rate of 3.2 per 1,000 person-years. That’s a 3.5-fold difference. The liver knows the difference between oral and transdermal. Your blood vessels do too.

Comparing the Three: Head-to-Head Where It Counts

For hot flash reduction, all three methods work equally well when properly dosed. The Canadian 2025 rapid review found no clinically meaningful difference in vasomotor symptom relief between the three routes. The choice is driven not by effectiveness — they’re all effective — but by safety, convenience, and tolerability.

Here’s how they compare across the key decision factors:

• Clot safety: Transdermal (patch or gel) carries near-background VTE risk. Oral pills increase VTE by 2- to 4-fold. For women with vascular risk factors, transdermal is the evidence-backed choice.
• Skin tolerance: Patch adhesives cause contact dermatitis in 10 to 25% of users. Gel and oral pills avoid this entirely.
• Cost: Oral pills cost $4 to $25 per month. Patches range $15 to $60. Gel runs $100 to $250 without insurance.
• Convenience: Twice-weekly patch wins for forgetfulness. Daily gel wins for dose flexibility. Daily pill wins for simplicity.
• Dose control: Gel allows the finest adjustments. Patches come in fixed strengths. Pills offer the narrowest titration range.

Estradiol implants — small pellets inserted under the skin every 4 to 6 months — are a fourth option worth mentioning. A 2025 review in the Journal of Clinical Medicine noted that pellet use has been documented since the 1940s and delivers sustained estradiol levels of 50 to 70 pg/mL without daily attention. But pellets require a minor in-clinic procedure for insertion and removal, and some providers are reluctant to use them due to limited FDA-approved pellet products and variable dosing control.

Progesterone Complicates the Equation

Women with a uterus need progestogen — either micronized progesterone or a synthetic progestin — to prevent endometrial hyperplasia when taking estrogen. The delivery method for progesterone matters too. Oral micronized progesterone (Prometrium, 200 mg for 12 days per month or 100 mg daily) is the standard. It also has the bonus side effect of improving sleep quality in many women due to its metabolite allopregnanolone.

The KEEPS trial used exactly this protocol: oral micronized progesterone 200 mg for 12 days per month alongside estradiol. The 2024 14-year follow-up found no increased breast cancer risk in the treatment groups compared to placebo — a finding that’s especially relevant because the WHI used a synthetic progestin (medroxyprogesterone acetate), not micronized progesterone. The type of progestogen may matter more than the type of estrogen for long-term safety outcomes.

Intrauterine progesterone (the Mirena IUD) is an alternative delivery method for the progestogen component, eliminating the systemic side effects of oral progesterone. Combined patches that include both estrogen and progestin are available and simplify the regimen to a single patch changed once or twice weekly.

How to Choose Your Delivery Method

Start with your medical history. If you’re at elevated risk for blood clots — from obesity, smoking, a personal or family history of VTE, or a known thrombophilia — transdermal is the evidence-backed choice. Period. The 2025 Canadian review and the 2026 AAFP guideline both say the same thing: transdermal estrogen for women with vascular risk factors.

If your skin is sensitive or you’ve had reactions to bandages, adhesive tapes, or previous patches, start with gel. If gel transfer risk is a concern — you have young children or a partner who shouldn’t be exposed to estrogen — consider oral pills or patches instead. If cost is the primary driver, oral pills win on price. If you want to apply a medication twice a week and forget about it, patches are the simplest option.

Whichever method you choose, monitor your symptoms for the first three months and adjust. The right delivery method is the one you’ll actually use consistently. For a deeper look at one specific method, read our detailed guide on menopause HRT patches.

The Bottom Line

Patches, gel, and pills all deliver the same hormone. But your body treats them differently because the delivery route changes how the hormone is processed. Transdermal routes — patches and gel — avoid the liver and carry lower clotting risk. Pills are cheaper but carry measurable additional risk that matters for certain patients. Gel offers flexible dosing but requires a 60-minute wait before contact. Patches are convenient but cause skin irritation for some women.

There’s no single best method. There’s only the best method for you. For a complete overview of menopause treatment options, visit our homepage.